Vitiligo is an autoimmune condition in which cells known as melanocytes are killed off in certain areas of the skin. Melanocytes produce melanin, a substance which gives the skin its pigmentation.

Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...